Mark Page

ORCID: 0000-0002-8664-133X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Monoclonal and Polyclonal Antibodies Research
  • Protein purification and stability
  • HIV Research and Treatment
  • Viral Infections and Outbreaks Research
  • Glycosylation and Glycoproteins Research
  • SARS-CoV-2 and COVID-19 Research
  • Hepatitis B Virus Studies
  • Virology and Viral Diseases
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • SARS-CoV-2 detection and testing
  • Virus-based gene therapy research
  • Viral Infections and Vectors
  • COVID-19 Clinical Research Studies
  • T-cell and B-cell Immunology
  • Blood groups and transfusion
  • Viral Infectious Diseases and Gene Expression in Insects
  • vaccines and immunoinformatics approaches
  • Disaster Response and Management
  • HIV/AIDS drug development and treatment
  • Immunodeficiency and Autoimmune Disorders
  • COVID-19 epidemiological studies
  • Hepatitis C virus research
  • Mosquito-borne diseases and control
  • Viral Infections and Immunology Research

National Institute for Biological Standards and Control
2013-2023

Government of the United Kingdom
2022-2023

London Clinic
2023

University Hospital of Geneva
2023

Action Cancer
2020-2022

University of Hertfordshire
2014

Potters Bar Community Hospital
2009-2012

University of Pretoria
2006

Basilea Pharmaceutica (Switzerland)
2006

University of York
2004

BackgroundAccurate quantitation of immune markers is crucial for ensuring reliable assessment vaccine efficacy against infectious diseases. This study was designed to confirm standardised performance SARS-CoV-2 assays used evaluate COVID-19 candidates at the initial seven laboratories (in North America, Europe, and Asia) Coalition Epidemic Preparedness Innovations (CEPI) Centralized Laboratory Network (CLN).MethodsThree ELISAs (pre-spike protein, receptor binding domain, nucleocapsid), a...

10.1016/s2666-5247(23)00324-5 article EN cc-by-nc-nd The Lancet Microbe 2024-01-23

A number of linear and conformation-dependent neutralizing monoclonal antibodies (MAbs) have been mapped to the first second variable (V1 V2) domains human immunodeficiency virus type 1 (HIV-1) gp120. The majority these MAbs are as effective at HIV-1 infectivity V3 domain CD4 binding site. bind amino acid residues 162 171, changes 183/184 (PI/SG) 191/192/193 (YSL/GSS) within V2 abrogate two MAbs, 11/68b CRA-4, respectively. Surprisingly, a change residue 435 (Y/H or Y/S), in region gp120...

10.1128/jvi.67.8.4932-4944.1993 article EN Journal of Virology 1993-08-01

Abstract The distribution of cytokeratins and vimentin intermediate filaments in the first 48 h chick development has been determined using immunofluorescent labelling. During formation germ layers, cytokeratin expression is associated with appearance an integral epithelium (ectoderm), whereas cells that detach migrate from this to form endoderm mesoderm. Subsequently, persists mesoderm tissues derived therefrom, such as somites developing heart, throughout period study. at later stages...

10.1242/dev.105.1.97 article EN Development 1989-01-01

The rise of SARS-CoV-2 variants has made the pursuit to define correlates protection more troublesome, despite availability World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin sera, a key reagent used standardise laboratory findings into an international unitage. Using pseudotyped virus, we examine capacity convalescent from well-defined cohort healthcare workers (HCW) and Patients infected during first wave national critical care centre in UK neutralise...

10.3389/fimmu.2022.773982 article EN cc-by Frontiers in Immunology 2022-03-07

In the first of two passive transfer experiments, three groups four macaques were injected intraperitoneally with a normal serum pool, an immune pool (pool 1) collected 132-172 weeks postinfection 11/88 SIVmac251, or neutralizing monoclonal antibodies (KK9, 17, 54, and 56) raised against gp120 pool. Sera given at dose 13 ml/kg whereas MAb was 30 ml/kg. second experiment, further 2) 12 simian-grown SIVmac251 19 Animals in both experiments challenged grown simian peripheral blood lymphocytes....

10.1089/aid.1994.10.189 article EN AIDS Research and Human Retroviruses 1994-02-01

Optimum strategies to elicit and maintain antibodies at mucosal portals of virus entry are critical for the development vaccines against human immunodeficiency (HIV). Here we show in non-human primates that a novel regimen repeated intravaginal delivery non-adjuvanted, soluble recombinant trimeric HIV-1CN54 clade C envelope glycoprotein (gp140) administered Carbopol gel can prime B-cell responses even absence seroconversion. Following 3 cycles administration, throughout each intermenses...

10.1016/j.vaccine.2010.12.034 article EN cc-by Vaccine 2010-12-26

Live attenuated measles virus is one of the most efficient and safest vaccines available, making it an attractive candidate vector for a HIV/AIDS vaccine aimed at eliciting cell-mediated immune responses (CMI). Here we have characterized potency CMI generated in mice non-human primates after intramuscular immunisation with recombinant carrying HIV-1 insert encoding Clade B Gag, RT Nef (MV1-F4). Eight Mauritian derived, MHC-typed cynomolgus macaques were immunised 105 TCID50 MV1-F4, four...

10.1371/journal.pone.0050397 article EN cc-by PLoS ONE 2012-11-30

The recent Ebola outbreak in West Africa led to the use of a variety different platform technologies for assaying antibodies because difficulties handling live virus. same types method could be applied rapidly other infections when they emerge. There is need compare quantitative results assays, which means that assays must measure similar parameters and give comparable results. A collaborative study was carried out establish an International Reference Reagent through WHO. Nine samples were...

10.1016/j.vaccine.2016.11.083 article EN cc-by-nc-nd Vaccine 2017-02-02

Abstract Precision monitoring of antibody responses during the COVID-19 pandemic is increasingly important large scale vaccine rollout and rise in prevalence Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2) variants concern (VOC). Equally defining Correlates Protection (CoP) for SARS-CoV-2 infection disease. Data from epidemiological studies trials identified virus neutralising antibodies (Nab) antigen-specific (notably RBD, S) binding as candidate CoP. In this study, we...

10.1101/2021.05.21.21257572 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2021-05-23

10.1016/j.cmi.2023.08.026 article EN publisher-specific-oa Clinical Microbiology and Infection 2023-09-03

Vaccination with live attenuated simian immunodeficiency virus (SIVmacC8) confers potent, reproducible protection against homologous wild-type challenge (SIVmacJ5). The ability of SIVmacC8 to confer resistance superinfection an uncloned ex vivo derivative SIVmac251 (SIVmac32H/L28) was investigated. In naïve, Mauritian-derived cynomolgus macaques (Macaca fascicularis), SIVmac32H/L28 replicated high peak titres (>10(8) SIV RNA copies ml(-1)), persisted at levels and induced distinctive...

10.1099/vir.0.2008/001693-0 article EN Journal of General Virology 2008-08-27

Myelin basic protein (MBP) is one of the main constituents CNS myelin sheaths, and an autoimmune response directed against MBP may be crucial in demyelination process patients with multiple sclerosis (MS). In this study sera cerebrospinal fluid (CSF) from 25 MS patients, other neurological diseases 16 healthy controls were examined for antibodies by using radio immunoblot, western blot, immunoassay enzyme-linked immunosorbant assay. No evidence presence to was found or CSFs either control...

10.1111/j.1600-0404.1994.tb02657.x article EN Acta Neurologica Scandinavica 2009-01-29

Vaccination of macaques with live attenuated simian immunodeficiency virus (SIV) provides significant protection against the wild-type virus. The use a human (HIV) as AIDS vaccine in humans is however considered unsafe because risk that may accumulate genetic changes during persistence and evolve to pathogenic variant. We earlier presented conditionally HIV-1 variant replicates exclusively presence doxycycline (dox). Replication this strain can be limited time needed provide full through...

10.1186/1742-4690-5-44 article EN cc-by Retrovirology 2008-06-05

Abstract During outbreaks of emerging viruses, such as the Zika outbreak in 2015–2016, speed and accuracy detection infection are critical factors to control spread disease; often serological diagnostic methods for viruses not well developed validated. Thus, vaccines treatments difficult evaluate due lack comparable methods. In this study, we show how 1st WHO International Standard anti-Zika antibody was able harmonize neutralization titres a panel Zika-positive samples from laboratories...

10.1038/s41541-019-0135-3 article EN cc-by npj Vaccines 2019-10-14
Coming Soon ...